Although potential long-term increased risk of second malignancy and cardiovascular disease in patients receiving G-CSF is intriguing and may have significant implications, the small size of the original study cohorts, lack of information on other known risk factors and the post hoc nature of this analysis limits the conclusions that can be drawn. This evidence concerns the gene CSF3 and cardiovascular disorder.